keyword
MENU ▼
Read by QxMD icon Read
search

Ceftaroline

keyword
https://www.readbyqxmd.com/read/28096164/pharmacodynamics-of-ceftaroline-plus-ampicillin-against-enterococcus-faecalis-in-an-in-vitro-pharmacokinetic-pharmacodynamic-model-of-simulated-endocardial-vegetations
#1
Brian J Werth, Laura M Shireman
The combination of ampicillin plus ceftaroline has been suggested to be more reliably synergistic against E. faecalis than ampicillin plus ceftriaxone using time-kill methods. The purpose of this study was to determine if this trend persists in a two-compartment-model of simulated endocardial vegetations(SEV) using clinically relevant pharmacokinetic exposures of these antimicrobials. Three clinically-derived E. faecalis strains were included in the study. The MICs of study antimicrobials were determined by broth microdilution...
January 17, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28069651/inhibition-by-avibactam-and-clavulanate-of-the-%C3%AE-lactamases-kpc-2-and-ctx-m-15-harboring-the-substitution-n132g-in-the-conserved-motif-sdn
#2
Clément Ourghanlian, Daria Soroka, Michel Arthur
The substitution N(132)G in the motif SDN of class A β-lactamases from rapidly-growing mycobacteria was previously shown to impair their inhibition by avibactam but to improve the stability of acyl-enzymes formed with clavulanate. The same substitution was introduced in KPC-2 and CTX-M-15 to assess its impact on β-lactamases from Enterobacteriaceae and evaluate whether it could lead to resistance to the ceftazidime-avibactam combination. Kinetic parameters for the inhibition of the β-lactamases by avibactam and clavulanate were determined by spectrophotometry using nitrocefin as the substrate...
January 9, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28061827/systematic-review-and-network-meta-analysis-of-tedizolid-for-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections-caused-by-mrsa
#3
Rachael McCool, Ian M Gould, Jacqui Eales, Teresa Barata, Mick Arber, Kelly Fleetwood, Julie Glanville, Teresa L Kauf
BACKGROUND: Tedizolid, the active moiety of tedizolid phosphate, is approved in the United States, the European Union, Canada and a number of other countries for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by certain susceptible bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). This network meta-analysis (NMA) evaluates the comparative effectiveness of tedizolid and other antibacterials indicated for the treatment of ABSSSI caused by MRSA...
January 7, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28058593/ceftaroline-fosamil-for-community-acquired-pneumonia-and-skin-and-skin-structure-infections-a-systematic-review
#4
Maguy Saffouh El Hajj, Ricky D Turgeon, Kyle John Wilby
Background Ceftaroline is a parentally administered cephalosporin that has an in vitro expanded spectrum of activity compared with other cephalosporins yet data is conflicting regarding its place in therapy. Aim of the Review To compare the efficacy and safety of ceftaroline against standard antibiotic regimens for community-acquired pneumonia (CAP) and complicated skin and skin structure infections (cSSSIs). Method The databases of MEDLINE, EBSCO, and Embase were searched up to June 2016. Manual review of references was completed and experts in the field were contacted for unpublished data...
January 5, 2017: International Journal of Clinical Pharmacy
https://www.readbyqxmd.com/read/28039666/use-of-ceftaroline-fosamil-in-children-review-of-current-knowledge-and-its-application
#5
REVIEW
Juwon Yim, Leah M Molloy, Jason G Newland
Ceftaroline is a novel cephalosporin recently approved in children for treatment of acute bacterial skin and soft tissue infections and community-acquired bacterial pneumonia (CABP) caused by methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae and other susceptible bacteria. With a favorable tolerability profile and efficacy proven in pediatric patients and excellent in vitro activity against resistant Gram-positive and Gram-negative bacteria, ceftaroline may serve as a therapeutic option for polymicrobial infections, CABP caused by penicillin- and ceftriaxone-resistant S...
December 30, 2016: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/28039276/the-pharmacodynamics-of-avibactam-in-combination-with-ceftaroline-or-ceftazidime-against-%C3%AE-lactamase-producing-enterobacteriaceae-studied-in-an-in-vitro-model-of-infection
#6
Alasdair MacGowan, Sharon Tomaselli, Alan Noel, Karen Bowker
OBJECTIVES: Pharmacodynamics of β-lactamase inhibitors are an area of intense interest as new β-lactam/β-lactamase inhibitor combinations enter clinical development and clinical practice. Avibactam, a non-β-lactam β-lactamase inhibitor, has been combined with ceftaroline or ceftazidime but these two combinations have not been directly compared. METHODS: Using an in vitro pharmacokinetic model we simulated human drug concentration-time courses associated with ceftaroline 600 mg every 8 h and ceftazidime 2000 mg every 8 h...
December 30, 2016: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/28038791/combination-therapy-with-vancomycin-and-ceftaroline-for-refractory-methicillin-resistant-staphylococcus-aureus-bacteremia-a-case-series
#7
Diana Gritsenko, Marianna Fedorenko, Jorg J Ruhe, Jerry Altshuler
PURPOSE: Although vancomycin has been the mainstay of therapy for methicillin-resistant Staphylococcus aureus (MRSA) infections, its effectiveness has been challenged. Combination therapy may be used for patients with persistent MRSA bacteremia refractory to initial therapy. Studies have reported in vitro synergy between vancomycin and ceftaroline; however, clinical experience with this therapy is limited. Here, we report our experience with 5 cases of vancomycin-refractory MRSA bacteremia treated with the combination of vancomycin and ceftaroline...
December 27, 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/28007722/physical-compatibility-of-isavuconazonium-sulfate-with-select-i-v-drugs-during-simulated-y-site-administration
#8
Wonhee So, Liz Kim, Abrar K Thabit, David P Nicolau, Joseph L Kuti
PURPOSE: The physical compatibility of isavuconazonium sulfate with 95 i.v. drugs during simulated Y-site administration was studied. METHODS: Isavuconazonium sulfate for injection and all other drugs were reconstituted according to the manufacturer's recommendation and further diluted with 0.9% sodium chloride injection or 5% dextrose injection to a final concentration (1.5 mg/mL for isavuconazonium sulfate and standard concentrations used clinically for other drugs)...
January 1, 2017: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/27977560/ceftaroline-activity-tested-against-bacterial-isolates-causing-community-acquired-respiratory-tract-infections-and-skin-and-skin-structure-infections-in-pediatric-patients-from-united-states-hospitals-2012-2014
#9
Michael A Pfaller, Rodrigo E Mendes, Mariana Castanheira, Robert K Flamm, Ronald N Jones, Helio S Sader
Ceftaroline fosamil has recently received United States Food and Drug Administration (US-FDA) approval for treatment of acute bacterial skin/skin structure infections (SSSI), including those caused by methicillin-resistant Staphylococcus aureus (MRSA) and community-acquired bacterial pneumonia for pediatric patients ≥2 months old. We evaluated the potency and spectrum of ceftaroline and comparators when tested against community-acquired respiratory tract (CARTI) and SSSI pathogens from pediatric patients...
December 12, 2016: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/27970753/zinforo-ceftaroline-fosamil-versus-other-empiric-initial-iv-antibiotics-for-complicated-skin-and-soft-tissue-infections-cssti-a-network-meta-analysis
#10
N Rao, E Gibson, R W Lawson, J J Goodall
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27970750/zinforo-ceftaroline-fosamil-versus-other-empiric-antibiotics-for-moderate-to-severe-community-acquired-pneumonia-cap-in-adults-a-network-meta-analysis
#11
N Rao, E Gibson, R W Lawson, J J Goodall
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27959289/newer-intravenous-antibiotics-in-the-intensive-care-unit-ceftaroline-ceftolozane-tazobactam-and-ceftazidime-avibactam
#12
Kathryn A Connor
No abstract text is available yet for this article.
October 2016: AACN Advanced Critical Care
https://www.readbyqxmd.com/read/27939093/susceptibility-to-cephalosporin-combinations-and-aztreonam-avibactam-among-third-generation-cephalosporin-resistant-enterobacteriaceae-recovered-on-hospital-admission
#13
Alexander Mischnik, Philipp Baumert, Axel Hamprecht, Anna Rohde, Silke Peter, Susanne Feihl, Johannes Knobloch, Hanna Gölz, Axel Kola, Birgit Obermann, Christiane Querbach, Matthias Willmann, Friedemann Gebhardt, Evelina Tacconelli, Petra Gastmeier, Harald Seifert, Winfried V Kern
As part of the multicentre Antibiotic Therapy Optimisation Study (ATHOS), minimum inhibitory concentrations (MICs) were determined for cephalosporins alone and in combination with the β-lactamase inhibitors tazobactam, clavulanic acid and avibactam against third-generation cephalosporin-resistant Escherichia coli, Klebsiella spp. and Enterobacter spp. isolates collected in German hospitals. MIC50/90 values were 0.25-4 mg/L for cefepime/tazobactam, 0.25-2 mg/L for ceftazidime/avibactam, 0.125-0.5 mg/L for ceftaroline/avibactam, 0...
November 28, 2016: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/27929242/community-acquired-pneumonia-in-adults-diagnosis-and-management
#14
Alexander Kaysin, Anthony J Viera
Community-acquired pneumonia is a leading cause of death. Risk factors include older age and medical comorbidities. Diagnosis is suggested by a history of cough, dyspnea, pleuritic pain, or acute functional or cognitive decline, with abnormal vital signs (e.g., fever, tachycardia) and lung examination findings. Diagnosis should be confirmed by chest radiography or ultrasonography. Validated prediction scores for pneumonia severity can guide the decision between outpatient and inpatient therapy. Using procalcitonin as a biomarker for severe infection may further assist with risk stratification...
November 1, 2016: American Family Physician
https://www.readbyqxmd.com/read/27918694/ceftaroline-activity-against-multidrug-resistant-streptococcus-pneumoniae-from-u-s-medical-centers-2014-and-molecular-characterization-of-a-single-ceftaroline-nonsusceptible-isolate
#15
Michael A Pfaller, Rodrigo E Mendes, Robert K Flamm, Ronald N Jones, Helio S Sader
Streptococcus pneumoniae isolates (2,614) were collected from patients at 135 U.S. Medical Centers during 2014. Isolates were evaluated for multidrug resistance to penicillin, ceftriaxone, erythromycin, tetracycline, trimethoprim-sulfamethoxazole, and levofloxacin. A single isolate (853008) demonstrated a ceftaroline nonsusceptible minimal inhibitory concentration (MIC) value, and it was subjected to molecular characterization. Ceftaroline (MIC50/90, ≤0.015/0.12 μg/ml) was eightfold more potent than ceftriaxone (MIC50/90, ≤0...
December 5, 2016: Microbial Drug Resistance: MDR: Mechanisms, Epidemiology, and Disease
https://www.readbyqxmd.com/read/27895012/a-multicenter-observational-study-of-ceftaroline-fosamil-for-methicillin-resistant-staphylococcus-aureus-bloodstream-infections
#16
Evan J Zasowski, Trang D Trinh, Kimberly C Claeys, Anthony M Casapao, Noor Sabagha, Abdalhamid M Lagnf, Kenneth P Klinker, Susan L Davis, Michael J Rybak
Novel therapies for methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection (BSI) are needed in the setting of reduced antibiotic susceptibilities and therapeutic failure. Ceftaroline is an advanced generation cephalosporin with MRSA activity. Although not FDA approved for MRSA BSI, ceftaroline has generated much interest as a potential treatment option. However, detailed description of its use in this setting remains limited. To address this, we conducted a retrospective, multicenter, observational study of adult patients with MRSA BSI treated with at least 72 hours of ceftaroline from 2011 to 2015...
November 28, 2016: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27890418/comparative-in-vitro-activity-of-oritavancin-and-other-agents-against-methicillin-susceptible-and-methicillin-resistant-staphylococcus-aureus
#17
Debora Sweeney, Dean L Shinabarger, Francis F Arhin, Adam Belley, Greg Moeck, Chris M Pillar
Methicillin-resistant Staphylococcus aureus (MRSA) infections constitute a threat to the public health due to their prevalence and associated mortality and morbidity. Several agents have been recently approved to treat MRSA skin infections including lipoglycopeptides (dalbavancin, oritavancin, and telavancin), ceftaroline, and tedizolid. This study compared the MIC, minimum bactericidal concentration (MBC), and time-kill of these agents alongside daptomycin, linezolid, and vancomycin against MRSA (n=15); meropenem, cefazolin, and nafcillin were also included against methicillin-susceptible S...
February 2017: Diagnostic Microbiology and Infectious Disease
https://www.readbyqxmd.com/read/27889013/methicillin-resistant-staphylococcus-aureus-infections-a-review-of-the-currently-available-treatment-options
#18
REVIEW
S M Purrello, J Garau, E Giamarellos, T Mazzei, F Pea, A Soriano, S Stefani
This review is the result of discussions that took place at the 5th MRSA Working Group Consensus Meeting and explores the possible treatment options available for different types of infections due to methicillin-resistant Staphylococcus aureus (MRSA), focusing on those antibiotics that could represent a valid alternative to vancomycin. In fact, whilst vancomycin remains a viable option, its therapy is moving towards individualised dosing. Other drugs, such as the new lipoglycopeptides (oritavancin, dalbavancin and telavancin) and fifth-generation cephalosporins (ceftaroline and ceftobiprole), are showing good in vitro potency and in vivo efficacy, especially for patients infected with micro-organisms with higher vancomycin minimum inhibitory concentrations (MICs)...
December 2016: Journal of Global Antimicrobial Resistance
https://www.readbyqxmd.com/read/27873126/resistance-to-non-glycopeptide-agents-in-serious-staphylococcus-aureus-infections
#19
REVIEW
Kyle C Molina, Vanthida Huang
The role of vancomycin in the treatment of serious Staphylococcus aureus infections, both methicillin-susceptible and methicillin-resistant, is becoming increasingly ineffective due to increasing MIC and failure. The development of reduced vancomycin susceptibility by S. aureus to glycopeptides highlights the need for clinicians to reexamine the roles of non-glycopeptide therapy. As the use of these alternative non-glycopeptides antimicrobials increases, it will become pertinent to monitor the rates of resistance...
December 2016: Current Infectious Disease Reports
https://www.readbyqxmd.com/read/27856079/in-vitro-activity-of-ceftobiprole-on-440-staphylococcus-aureus-strains-isolated-from-bronchopulmonary-infections
#20
E Hodille, L Delouere, C Bouveyron, H Meugnier, M Bes, A Tristan, F Laurent, F Vandenesch, G Lina, O Dumitrescu
OBJECTIVE: We assessed the in vitro activity of ceftobiprole on 440 Staphylococcus aureus clinical strains isolated from bronchopulmonary infections (2010-2014). METHODS: S. aureus isolates were characterized for methicillin resistance, PVL status, and clonal complex. All isolates were tested for minimal inhibitory concentrations (MIC) determination by broth microdilution method for ceftobiprole, ceftaroline fosamil, and comparator antibiotics (linezolid, tigecycline, vancomycin, and daptomycin)...
November 14, 2016: Médecine et Maladies Infectieuses
keyword
keyword
21356
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"